Literature DB >> 22087695

Chimeric antigen receptor-modified T cells in CLL.

James N Kochenderfer, Steven A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22087695      PMCID： PMC6348466          DOI： 10.1056/NEJMc1111004

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

Review 1.  CD19 as an attractive target for antibody-based therapy.

Authors:  Ohad Hammer
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

2.  Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape.

Authors:  Karen M Kaluza; Timothy Kottke; Rosa Maria Diaz; Diana Rommelfanger; Jill Thompson; Richard Vile
Journal:  Hum Gene Ther       Date:  2012-08-13       Impact factor: 5.695

3.  Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.

Authors:  I Pizzitola; F Anjos-Afonso; K Rouault-Pierre; F Lassailly; S Tettamanti; O Spinelli; A Biondi; E Biagi; D Bonnet
Journal:  Leukemia       Date:  2014-02-07       Impact factor: 11.528

Review 4.  Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Authors:  Nathan H Fowler; Chan Yoon Cheah; Randy D Gascoyne; John Gribben; Sattva S Neelapu; Paolo Ghia; Catherine Bollard; Stephen Ansell; Michael Curran; Wyndham H Wilson; Susan O'Brien; Cliona Grant; Richard Little; Thorsten Zenz; Loretta J Nastoupil; Kieron Dunleavy
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

5.  Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.

Authors:  Nicolas Acquavella; David Clever; Zhiya Yu; Melody Roelke-Parker; Douglas C Palmer; Liqiang Xi; Holger Pflicke; Yun Ji; Alena Gros; Ken-Ichi Hanada; Ian S Goldlust; Gautam U Mehta; Christopher A Klebanoff; Joseph G Crompton; Madhusudhanan Sukumar; James J Morrow; Zulmarie Franco; Luca Gattinoni; Hui Liu; Ena Wang; Francesco Marincola; David F Stroncek; Chyi-Chia R Lee; Mark Raffeld; Marcus W Bosenberg; Rahul Roychoudhuri; Nicholas P Restifo
Journal:  Cancer Immunol Res       Date:  2014-10-30       Impact factor: 11.151

6.  TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy.

Authors:  Zakaria Grada; Meenakshi Hegde; Tiara Byrd; Donald R Shaffer; Alexia Ghazi; Vita S Brawley; Amanda Corder; Kurt Schönfeld; Joachim Koch; Gianpietro Dotti; Helen E Heslop; Stephen Gottschalk; Winfried S Wels; Matthew L Baker; Nabil Ahmed
Journal:  Mol Ther Nucleic Acids       Date:  2013-07-09       Impact factor: 10.183

Review 7.  Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.

Authors:  Zhenguang Wang; Yelei Guo; Weidong Han
Journal:  Protein Cell       Date:  2017-05-02       Impact factor: 14.870

8.  CD81 costimulation skews CAR transduction toward naive T cells.

Authors:  Liora M Schultz; Debra K Czerwinski; Ronald Levy; Shoshana Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-01       Impact factor: 12.779

Review 9.  Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.

Authors:  Liora Schultz
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.